Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravitreal recombinant tPA to facilitate vitrectomy for diabetic tractional retinal detachment
IRCT20200217046522N1Phase 3Completed
- Sponsor
- Iran University of Medical Sciences
- Start
- Dec 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in retinal detachment comparing rtPA + bevacizumab with Sham + bevacizumab (2 arms). Primary endpoint: Post surgical anatomical success rate. Started Dec 2019; status: completed.
02
Drugs
tissue-plasminogen activatorbevacizumab
03
Conditions
retinal detachment
Beyond the preview
Go deeper on IRCT20200217046522N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200217046522N1.